Effect of Favipiravir on Mortality in Patients With COVID-19 at a Tertiary Center Intensive Care Unit

Effect of Favipiravir on Mortality in Patients With COVID-19 at a Tertiary Center Intensive Care Unit: Single Center Experience

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04645433

Enrollment

100

Registered

2020-11-27

Start date

2020-03-15

Completion date

2020-05-15

Last updated

2020-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intensive Care Unit, Mortality

Keywords

covid 19, favipiravir

Brief summary

Effect of Favipiravir and Lopinavir-Ritonavir on Mortality in a Tertiary Center Intensive Care Unit: Single Center Experience

Detailed description

Many agents have been given for treatment of COVID-19 infection. Covid-19 Diagnosis and Treatment Guideline by Ministry of Health was advised nationwide use of favipiravir or lopinavir-ritonavir although evidence was scarce for the nationwide use of lopinavir-ritonavir or favipiravir to treat COVID-19 at the time of publication date of detailed guideline Favipiravir is a RNA dependent RNA polymerase inhibitor and approved for treatment of influenza in Japan at 2014 The aim of the study was to compare ICU and hospital mortality in patients with favipiravir or lopinavir-ritonavir treatment and compare other laboratory parameters in patients treated with these two antiviral agents.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* 18 Years and older

Exclusion criteria

* patients younger than 18 years old * patients who have received both lopinavir-ritonavir and favipiravir sepuentially

Design outcomes

Primary

Measure	Time frame	Description
Mortality for ICU	14 days	If the patient dies, we have reached an outcome
hospital stay	14 days	If the hospital stay exceeds 14 days, we have reached an outcome

Countries

Turkey (Türkiye)

Outcome results